SAN DIEGO, June 12, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that its commercialization partner, Alvogen, has launched Teriparatide Injection in the United States.

RANCHO CUCAMONGA, CA / ACCESS Newswire / May 27, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that ... · ACCESS Newswire · Amphastar Pharmaceuticals, Inc. Amphastar ...

PARSIPPANY, N.J. & TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the approval of a ...

July 24, 2009 — The US Food and Drug Administration (FDA) has approved an expanded indication for teriparatide (rDNA origin) injection (Forteo, Eli Lilly and Company, Inc) for the treatment of ...

Please provide your email address to receive an email when new articles are posted on . Teriparatide administered through the RT-102 pill provided higher bioavailability than injection with no ...

Forteo (teriparatide) is a brand-name medication that doctors may prescribe to treat osteoporosis. The drug uses proteins to enhance bone strength and promote the development of new bone tissue. You ...

(HealthDay)—Daily injection of teriparatide significantly reduces the incidence of pedicle screw (PS) loosening at one year following surgery to correct degenerative spondylolisthesis in osteoporotic ...

INDIANAPOLIS, May 29, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data showing that FORTEO significantly increased lumbar spine volumetric bone mineral density (vBMD) ...

Teriparatide is an injectable drug to treat severe osteoporosis, a condition where mineral loss causes the bones to become brittle and to fracture easily. Teriparatide improves bone strength by ...

Please provide your email address to receive an email when new articles are posted on . The use of teriparatide injections at least 1 month prior to surgery effectively increased the insertional ...

today announced new data showing that FORTEO significantly increased lumbar spine volumetric bone mineral density (vBMD) compared to risedronate in men with glucocorticoid-induced osteoporosis.